Promising Early Data from GI Malignancy Trials
Tanios S. Bekaii-Saab, MD shares his perspective on exciting breakthroughs in GI malignancy research and treatment, focusing on HER2, BRAF V600E, and KRAS g12c.
EP: 1.Recent Advancements and Current Areas of Focus in the Treatment of mCRC
EP: 2.HER2 as a Potential Drug Target and its Prevalence in GI Malignancies
EP: 3.Biomarker Testing and Next-Generation Sequencing Inform Modern Treatment Strategies for mCRC
EP: 4.MOUNTAINEER Trial: Rationale, Results and Clinical Implications
Now Viewing
EP: 5.Promising Early Data from GI Malignancy Trials
Related Videos
Related Content
